Pseudotumor Surgery in Haemophilia a Patient: Comparative Results between Inhibitor and Non-Inhibitor Patients

Introduction: The Haemophilic Pseudotumour (HP) is an encapsulated hematoma which has a tendency to progress and produce clinical symptoms. It is a rare but serious complication of haemophilia. The current standard curative treatment for all pseudotumours is surgical. Aim: The aim of this study is to show surgical results and complications in both Inhibitor Patients (IP) and Non-Inhibitor Patients (NIP) with pseudotumors. Patients and Methods: Fourteen patients with severe haemophilia A were treated for pseudotumor in the Haemophilia Foundation in Buenos Aires, Argentina between 2000 and 2012. Seven of these patients are Non Inhibitor Patients (NIP), and 7 are Inhibitors Patients (IP). Patients were evaluated for use of factor in the post-op period, duration of surgery, transfusions requirements and length of hospitalization after surgery. All data were analysed using the Kolmogorov-Smirnov test for non-parametric independent samples. Results: There were no differences between groups of non-inhibitor and inhibitor patients regarding blood transfusion requirements, length of hospitalization stay and days on replacement or by-passing therapy. Conclusion: Our results show that, if proper haemostatic coverage is provided, pseudotumor surgery in inhibitor patients is at least as feasible as in non-inhibitor patients when the mini invasive technique is used. The present compares treatment outcomes in both inhibitor and non inhibitor patients with pseudotumors with similar characteristics. with